On the Horizon- Patupilone in Patients with Metastatic Castration-Resistant Prostate Cancer who have Progressed after Docetaxel – A Phase II Study

Once we have failed docetaxel therapy (chemo therapy) we have very few options available to control advanced prostate cancer. There is a recnt report about a clinical trial using a new potential drug, Patupilone. Patupilone has shown some evidence that it exhibits a limited positive effect in the pre-clinical setting in taxane resistant models of [...]

Chemo Brain – Yes, Prostate Cancer Survivors Do Suffer From It

Today’s New York Times has published another of its fantastic articles about cancer and coping with cancer. Today’s article, written by Jane Brody, discusses chemo brain. Until a short time ago, many doctors denied that it even existed, but today it is pretty much accepted as being real. One is said to suffer from chemo [...]

Mitoxantrone Plus Prednisone – A Possible Fallback After Taxotere Failure

Men with metastatic hormone-refractory prostate cancer (mHRPC) who become docetaxel-refractory (no longer responsive to docetaxel therapy have no approved second line chemotherapy available. One could say that they have reached the proverbial brick wall. Where to go and what to do is not at all clear. Most of us do not want to just roll [...]

Increased Levels of C-Reactive Protein is Confirmed to Limit Survival

A presentation at the ASCO conference in Florida reconfirmed the fact that increased levels of C-reactive protein (CRP) is associated with adverse outcomes (earlier death) in men with castration-resistant prostate cancer (CRPC) treated with docetaxel (taxotere). The study analyzed the baseline serum samples from 119 castrate resistant (CRPC) men enrolled in 6 phase I or [...]

Increased Survival Demonstrated in a Phase II Trial of OGX-011

Results from a randomized phase II study presented Saturday at the American Society of Clinical Oncology (ASCO) annual meeting indicates there might be a new drug on the horizon for men with advanced prostate cancer. OncoGenex Pharmaceuticals drug known as OGX-011 extended the survival of patients with advanced prostate cancer by almost seven months in [...]

Nausea, Vomiting & Chemotherapy

One of the more common side effects from Taxotere (chemotherapy) is nausea. People often refer to this side effect as retching, stomach ache, throwing up, queasy, heart burn, motion sickness, dry heave, puke, and feeling sick to my stomach. However, not everyone experiences nausea. There are many drugs (these medications are called anti-nausea drugs or [...]

Docetaxel-Based Chemotherapy in Elderly Patients (Age 75 and Older) with Castration-Resistant Prostate Cancer Is Viable

There have been very few studies on the patterns of care and outcome of elderly (over 75 years) survivors with androgen independent prostate cancer (AIPC) who have been treated with docetaxel (Taxotere). The records of 175 French men with AIPC, over the age of 75 years, were retrospectively examined. All of the men were treated [...]

Chemotherapy Is Not So Difficult – A survey

Last April HealthDay News ran an article about chemotherapy and patients fear about starting it. Most cancer survivors involved in a recent survey reported that they had been fearful of undergoing chemotherapy. The good news is that most also said the treatments were much less difficult than they had expected. The truly startling fact is [...]

Fasting Might Limit Chemotherapy’s Side Effects- A Potential New Paradigm For Taxotere Administration

You are scheduled for chemotherapy (Taxotere if you are being treated for prostate cancer) in a few days, so you stop eating until you complete the therapy session! This scenario could become typical in future treatment protocols. Published last week in Proceedings of the National Academy of Sciences was a study that found that starving [...]

Chemotherapy – Its Administration and Side Effects

Taxotere (chemotherapy for prostate cancer) is administered intravenously usually in an cancer center or a hospital setting. Often the areas which are designated for chemo administration are referred to as infusion centers. Taxotere is administered with either on a higher dosage schedule of once every three weeks (q3wk) or a lower dosage schedule of once [...]

Go to Top